Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 CAD | 0.00% | -5.88% | +23.08% |
Mar. 27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% | MT |
Mar. 27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows | MT |
Sales 2024 * | 43.06M 31.48M | Sales 2025 * | 58.43M 42.71M | Capitalization | 32.34M 23.64M |
---|---|---|---|---|---|
Net income 2024 * | -7M -5.12M | Net income 2025 * | -1M -731K | EV / Sales 2024 * | 0.75 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.55 x |
P/E ratio 2024 * |
-5.33
x | P/E ratio 2025 * |
-
| Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.53% |
Latest transcript on MediPharm Labs Corp.
1 week | -5.88% | ||
Current month | -15.79% | ||
1 month | -5.88% | ||
3 months | +14.29% | ||
6 months | +14.29% | ||
Current year | +23.08% |
Managers | Title | Age | Since |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 22-04-19 |
Greg Hunter
DFI | Director of Finance/CFO | - | 21-02-07 |
Keith Strachan
PSD | President | - | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 23-03-31 |
David Pidduck
CEO | Chief Executive Officer | - | 22-04-19 |
Shelley Martin
BRD | Director/Board Member | - | 20-06-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.83% | 0 M€ | +27.40% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.08 | 0.00% | 23,872 |
24-05-09 | 0.08 | -5.88% | 64,620 |
24-05-08 | 0.085 | +6.25% | 24,203 |
24-05-07 | 0.08 | -11.11% | 99,267 |
24-05-06 | 0.09 | +5.88% | 88,606 |
Delayed Quote Toronto S.E., May 10, 2024 at 03:12 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.08% | 23.67M | |
+40.09% | 6.16B | |
-16.34% | 4.46B | |
-7.11% | 3.27B | |
+5.14% | 3.2B | |
-0.18% | 2.6B | |
+47.93% | 1.98B | |
-7.15% | 1.7B | |
+0.67% | 1.66B | |
-8.73% | 1.61B |
- Stock Market
- Equities
- LABS Stock